Iclaprim (CAS 192314-93-5)

Iclaprim, bearing the CAS number 192314-93-5, is a diaminopyrimidine antibiotic that has been actively employed in research to explore its unique mechanism of action and its potential role in combating bacterial growth through inhibition of folate metabolism. Specifically, Iclaprim functions by selectively inhibiting bacterial dihydrofolate reductase (DHFR), an enzyme critical for the thymidine and purine synthesis necessary for DNA replication and cell division. This inhibition disrupts the folate cycle, thereby preventing the bacteria from synthesizing the DNA, RNA, and proteins essential for their growth and multiplication. Iclaprim′s high affinity for bacterial DHFR, compared to its affinity for mammalian DHFR, makes it a particularly interesting subject in the study of selective toxicity and bacterial resistance mechanisms. In research contexts, Iclaprim has been notably useful in detailed studies of bacterial resistance development, particularly in how mutations in the DHFR gene may confer resistance to dihydrofolate reductase inhibitors. Additionally, due to its unique mechanism and potent activity against a wide range of Gram-positive pathogens, Iclaprim has been utilized in studies aiming to understand cross-resistance patterns with other antibiotics and in investigations of synergistic effects when used in combination with other antimicrobial agents. These research efforts contribute significantly to the broader scientific understanding of microbial pathogenesis and resistance.